SGLT-2i and GLP-1RA therapies are now considered as options for treatment, independent of A1c levels, and are instead indicated based on the presence of established ASCVD or notable risk factors for arteriosclerotic vascular disease (ASVD), as well as heartfailure and/or CKD.
Glp-1 Treatment Of T1D
The latest entrant, Zepbound, recently joined Ozempic, Wegovy, Victoza and others in a growing class of drugs called GLP-1 receptor agonists. With about half a dozen drugs to choose from now and more in development, many doctors say these medications are revolutionizing treatment of...
Treatment with GLP-1 MSC led to a reduction of astrocytosis as detected by GFAP (glial fibrillary acidic protein) staining in lumbar spinal cord sections compared to vehicle treated controls even though quantitative analysis was not statistically significant (figure 4B).
